Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancerAlessandro Leonetti, Elisa Giovannetti, Birgit M. M. Wever et al.|Drug Resistance Updates|2019Cited by 198
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Luis E. Raez, Rossana Ruiz et al.|Expert Opinion on Investigational Drugs|2015Cited by 153
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancerChristian Rolfo, Aung Naing, Elisa Giovannetti et al.|npj Precision Oncology|2023Cited by 146
Immunotherapy in NSCLC: A Promising and Revolutionary WeaponChristian Rolfo, Mauricio Mahave, Christian Caglevic et al.|Advances in experimental medicine and biology|2017Cited by 143
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transitionAntonino Glaviano, Alan Prem Kumar, Hannah Lau et al.|Journal of Hematology & Oncology|2025Cited by 128